Results 261 to 270 of about 264,257 (370)

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Journal of Clinical Oncology, 2006
T. Habermann, E. Weller, V. Morrison, R. Gascoyne, P. Cassileth, J. Cohn, S. Dakhil, B. Woda, R. Fisher, B. Peterson, S. Horning   +10 more
semanticscholar   +1 more source

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

British Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian, Chiara Arrigoni, Francesco Bertoni, Matteo Moretti   +12 more
wiley   +1 more source

Rare Clinical Presentation of Diffuse Large B-Cell Lymphoma as Otitis Media and Mastoiditis. [PDF]

J Audiol Otol
Joo HA, Park HJ.
europepmc   +1 more source

Orbital MALT Lymphoma, Abdominal Hodgkin lymphoma, and Systemic Diffuse Large B-cell Lymphoma Develop Sequentially in One Patient

, 2012
Toshihiko Matsuo, Kouichi Ichimura, Katsuji Shinagawa   +2 more
openalex   +2 more sources

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Cell, 2017
Anupama Reddy, Jenny Zhang, Nicholas S. Davis, Andrea B. Moffitt, C. Love, A. Waldrop, S. Leppa, A. Pasanen, L. Meriranta, M. Karjalainen-Lindsberg, P. Nørgaard, M. Pedersen, A. Gang, E. Høgdall, Tayla B. Heavican, Waseem G Lone, J. Iqbal, Qiu Qin, Guojie Li, S. Kim, J. Healy, K. Richards, Y. Fedoriw, L. Bernal-Mizrachi, J. Koff, A. Staton, C. Flowers, O. Paltiel, N. Goldschmidt, M. Calaminici, A. Clear, J. Gribben, Evelyn T. Nguyen, M. Czader, S. Ondrejka, A. Collie, E. Hsi, E. Tse, R. Au-Yeung, Y. Kwong, G. Srivastava, W. Choi, A. Evens, M. Pilichowska, M. Sengar, N. Reddy, Shaoying Li, A. Chadburn, L. Gordon, E. Jaffe, S. Levy, R. Rempel, Tiffany J Tzeng, Lanie E. Happ, Tushar Dave, D. Rajagopalan, J. Datta, D. Dunson, S. Dave   +58 more
semanticscholar   +1 more source

Diffuse Large B-Cell Lymphoma in 2016

Journal of Clinical and Experimental Hematopathology, 2016
openaire   +3 more sources

Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Nicolas Munz, Alberto J. Arribas, Roberta Bordone Pittau, Federico Simonetta, Georg Stussi, Francesco Bertoni   +5 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Between Blood and Tumor: Retroperitoneal Hematoma Look-Alike Revealed as Diffuse Large B-Cell Lymphoma. [PDF]

Cureus
Dar UA, Zakhireh B, Hakim N, Kim B, Didia C.   +4 more
europepmc   +1 more source

Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome

, 2006
康志 小島
openalex   +1 more source